The presence of cardiovascular comorbidities has minimal effect on the efficacy of inhaled or oral treprostinil when used alongside oral monotherapy in patients with pulmonary arterial hypertension (PAH).

"Results from this post hoc analysis suggest that sequential combination therapy with oral or inhaled treprostinil and another background PAH therapy may also be a treatment option for this patient population with cardiovascular comorbidities," the authors wrote.

The study was led by R. James White, MD, PhD, University of Rochester Medical Center, Rochester, New York. It was published online on November 29, 2024, in CHEST.

The study did not include low diffusing capacity of the lungs for carbon monoxide as a comorbid condition, limiting the ability to fully characterize the patient population. Additionally, in the FREEDOM-EV study, patients with three or more risk factors for left ventricular disease were excluded, potentially limiting the applicability to individuals with a greater burden of cardiovascular comorbidities.

This study was supported by the United Therapeutics Corporation. Several authors reported receiving speaker fees, consulting fees, honoraria, travel and accommodation, support for scientific meetings, and research funding and serving on advisory boards or as consultants for various pharmaceutical organizations.